Form 8-K - Current report:
SEC Accession No. 0001839882-24-002578
Filing Date
2024-01-31
Accepted
2024-01-31 07:05:31
Documents
15
Period of Report
2024-01-31
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT txnp_8k-013124.htm   iXBRL 8-K 28509
2 PRESS RELEASE ex99-01.htm EX-99.1 20491
  Complete submission text file 0001839882-24-002578.txt   229127

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tnxp-20240131.xsd EX-101.SCH 3003
4 XBRL LABEL FILE tnxp-20240131_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tnxp-20240131_pre.xml EX-101.PRE 22351
16 EXTRACTED XBRL INSTANCE DOCUMENT txnp_8k-013124_htm.xml XML 3477
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 24580619
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)